Pharmaceuticals

Daiichi Sankyo

Daiichi Sankyo Partners with Urban Cancer Challenge to Launch 3-Year Initiative Supporting WHO Breast Cancer Program

Daiichi Sankyo Receives FDA Approval for Enhertu in Early-Stage Breast Cancer, Triggering $155M Milestone Payment from AstraZeneca

FDA approves T-DXD for two new indications in HER2+ early breast cancer and companion diagnostics

Daiichi Sankyo released FY2026 Q4 earnings on May 11 After-Market EST, actual revenue USD 3.692 B (forecast USD 3.754 B), actual EPS USD 0.1441

Daiichi Sankyo released FY2026 earnings on May 11 After-Market EST, actual revenue USD 13.99 B (forecast USD 13.36 B), actual EPS USD 0.925

Daiichi Sankyo reports quarterly earnings and upgrades stock rating

Daiichi Sankyo Updates FY2026 Earnings Guidance

Daiichi Sankyo Announces 2030 Fiscal Year Goals and Strategies

Daiichi Sankyo Healthcare to Raise Drug Prices Up to 40%

Daiichi Sankyo to Release FY2026 Earnings on May 11 After-Market EST, Forecast Revenue USD 13.35 B

Daiichi Sankyo's Pexidartinib Fails to Gain Approval in China

Daiichi Sankyo to Release Quarterly Earnings Report

Daiichi Sankyo to release FY2026 earnings on April 27 during market hours (EST), forecast revenue USD 13.35 B

Daiichi Sankyo to release FY2026 Q4 earnings report on April 26 During-Market EST, forecast revenue USD 3.697 B

Suntory Holdings Plans to Acquire Daiichi Sankyo Healthcare

DSK's IFINATAMAB DERUXTECAN Granted Priority Review in the U.S.

ATLATL Innovation Center Reaches Biotech Innovation Cooperation Agreement with Daiichi Sankyo

AstraZeneca and Daiichi Sankyo's Enhertu Approved in China for HER2-Positive Breast Cancer Neoadjuvant Therapy

Daiichi Sankyo Receives Approval for New Drug Enhertu

AstraZeneca and Daiichi Sankyo Obtain Fast Track Qualification for American Cancer Drugs

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

AstraZeneca

Daiichi Sankyo Company, Limited

AstraZeneca PLC

FDA approves Enhertu for two HER2-positive early breast cancer indications

DSNKY

4568

The FDA has expanded the use of Enhertu (trastuzumab deruxtecan) for HER2-positive Stage II and III breast cancer, approving it for neoadjuvant and adjuvant settings. The neoadjuvant approval is based on the DESTINY-Breast11 trial, showing a 67.3% pathologic complete response. The adjuvant approval, based on DESTINY-Breast05, demonstrated a 53% reduction in recurrence risk. These approvals enhance treatment options and have significant financial implications, including $155 million in milestone payments.

Pharmexec

<![CDATA[FDA Expands Enhertu in Early HER2-Positive Breast Cancer]]>

The FDA has approved AstraZeneca and Daiichi Sankyo's ENHERTU for neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on Phase III trial results. ENHERTU is now approved for adult patients with Stage II or III breast cancer and those with residual disease post-treatment. It is already approved in over 95 countries for metastatic breast cancer.

rttnews

AZN :FDA Approves ENHERTU For HER2-Positive Early Breast Cancer In Neoadjuvant And Adjuvant Settings

FDA cleared Enhertu for two more Stage 2–3 breast cancer uses. AstraZeneca co-develops/commercializes the drug and owes Daiichi Sankyo a $155M milestone; U.S. sales credited to Daiichi Sankyo.1FDA official Tracey Hoeg flagged safety questions about AstraZeneca PLC's infant RSV preventive during agency review of RSV treatments, prompting renewed regulatory scrutiny relevant to AZN traders.2

TradingView

Key facts: Enhertu Cleared for Two Breast Uses; Safety Flag on AZ RSV

Daiichi Sankyo (OTCMKTS:DSNKY) announced its quarterly earnings, reporting an EPS of $0.15, a net margin of 14.83%, and a return on equity of 18.64%. The company updated its FY 2026 guidance to $0.910 EPS. The stock traded at $17.12 with a market cap of $32.43 billion. Analysts have upgraded the stock from "strong sell" to "hold," with an average rating of "buy."

Market Beat

Merck

Daiichi Sankyo (OTCMKTS:DSNKY) Announces Earnings Results

Daiichi Sankyo (OTCMKTS:DSNKY) has updated its FY 2026 earnings guidance, projecting EPS of 0.910, below the consensus estimate of 1.040. The company also forecasts revenue of $14.5 billion, exceeding the consensus estimate of $13.4 billion. The stock rose 1.8% to $16.80, with a market cap of $31.83 billion and a PE ratio of 15.41. Analysts have upgraded the stock from "strong sell" to "hold," with a consensus rating of "Buy."

Apple

Astellas Pharma Inc.

Daiichi Sankyo (OTCMKTS:DSNKY) Issues FY 2026 Earnings Guidance

Daiichi Sankyo Co. Ltd. reported a 12.1% decline in net income for the fiscal year ending March 31, 2026, with profit attributable to owners at 259.87 billion yen. Earnings per share fell to 140.37 yen. Despite a revenue increase to 2.12 trillion yen, operating profit dropped 31% to 229.09 billion yen. For FY27, the company projects revenue of 2.28 trillion yen and profit of 260 billion yen, with earnings per share expected at 142.88 yen. The stock rose 2.04% to JPY 2,649 on the Tokyo Stock Exchange.

Daiichi Sankyo Earnings Fall; Guides FY27

Daiichi Sankyo has unveiled a new Five-Year Business Plan (FY2026 - FY2030) aimed at achieving over 2.3 trillion yen in oncology revenue by 2030 and becoming a top five global oncology company by 2035. The plan focuses on launching 20 new indications across five medicines, enhancing clinical development capabilities, and leveraging its DXd antibody drug conjugate platform. Financial targets include an operating profit exceeding 600 billion yen by 2030 and a progressive dividend policy. The company aims to accelerate innovation through advanced research and operational excellence, contributing to sustainable healthcare solutions.

MorningStar

Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation

Daiichi Sankyo and Waiv partner for ADC biomarkers

Daiichi Sankyo(DSNKY.US)